AstraZeneca plc vs Cassava Sciences Inc — how do they compare? AstraZeneca plc trades at $157.96 (market cap $248.14B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: AstraZeneca plc is far larger — about 5196.6× Cassava Sciences Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| AZN | FLNA | |
|---|---|---|
Market Cap | $248.14B | $47.75M |
Sector | Health | Health |
52-Week High | $209.48 | $4.64 |
52-Week Low | $147.06 | $0.87 |
Enterprise Value | $275.41B | -$34.93M |
Dividend Yield | 2.01% | — |
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →